Search research articles
Contact Us
Filters
Showing results (181-190 of 200) with videos related to
Page
of 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2018
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes
L Bonanno, A Pavan, M V Dieci, et al.
British Journal of Cancer
|
January 8, 2004
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
F Cappuzzo, F Mazzoni, A Gennari, et al.
The Pharmacogenomics Journal
|
July 6, 2016
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
A Musolino, N Naldi, M V Dieci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1996
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
M Venturini, A Michelotti, L Del Mastro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest
P F Conte, M Bruzzone, F Carnino, et al.
Cancer Treatment Reviews
|
January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
July 3, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
May 7, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
British Journal of Cancer
|
July 30, 2005
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
P F Conte, S Donati, A Gennari, et al.
Gynecologic Oncology
|
June 1, 1997
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest
M Bruzzone, A Rubagotti, A Gadducci, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 200) with videos related to
Sort By:
Page
of 20
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2018
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes
L Bonanno, A Pavan, M V Dieci, et al.
British Journal of Cancer
|
January 8, 2004
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
F Cappuzzo, F Mazzoni, A Gennari, et al.
The Pharmacogenomics Journal
|
July 6, 2016
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
A Musolino, N Naldi, M V Dieci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1996
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
M Venturini, A Michelotti, L Del Mastro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest
P F Conte, M Bruzzone, F Carnino, et al.
Cancer Treatment Reviews
|
January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
July 3, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
May 7, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
British Journal of Cancer
|
July 30, 2005
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
P F Conte, S Donati, A Gennari, et al.
Gynecologic Oncology
|
June 1, 1997
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest
M Bruzzone, A Rubagotti, A Gadducci, et al.
Page
of 20